Related Experiment Video
Updated: Jul 3, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Characterization of new formalin-detoxified botulinum neurotoxin toxoids
1Division of Bacterial, Parasitic and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. james.keller@fda.hhs.gov
Abstract:
Antigenicities of several formalin-detoxified botulinum neurotoxin preparations were measured by inhibition and sandwich enzyme-linked immunosorbent assay (ELISA), and immunogenicity was studied in mice. The toxoids were derived primarily from the serotype A 150-kDa neurotoxin protein, while one toxoid was derived from the naturally occurring 900-kDa toxin-hemagglutinin complex. Antigenicity was severely compromised in two commercially available toxoids. A variety of new toxoids were synthesized in-house by optimizing formaldehyde reaction conditions. Three of the resulting toxoids were found to be antigenically identical to the native toxin, as measured by inhibition ELISA, in spite of showing a reduction of toxicity by more than 100,000-fold. Sandwich ELISAs indicated that the in-house toxoids were two- to threefold less antigenic than the neurotoxin compared to commercial toxoids, which were about 100-fold less antigenic. Mice were immunized twice, on day 0 and day 14. By day 28, relatively high toxin-specific immunoglobulin G (IgG) titers were detected in animals that had received any of the in-house toxoids, with greater than 99% being IgG1 and the remainder being IgG2. These immunized mice remained asymptomatic after being challenged with 50 to 1,000,000 50% lethal dose (LD(50)) units of the 900-kDa neurotoxin. In contrast, animals immunized with several different batches of commercially available toxoids did not develop measurable toxin-specific antibody titers. However, these mice survived neurotoxin challenges with 2 LD(50) units but died when challenged with 6 LD(50) units. Neutralizing titers measured from pools of sera generated with the in-house toxoid preparations ranged from 2.5 to 5 U/ml. In terms of predicting immunogenicity, inhibition ELISAs comparing each formalin toxoid to the parent toxin provided good insight for screening the new toxoids as well as for estimating their relative in vivo potencies. Inhibition ELISA data indicate that those toxoids that most closely resemble the native toxin are highly immunogenic and protective. The superior quality of these new toxoids makes them useful tools for continued use in ELISA development and for antitoxin production.
Insights
New formalin-detoxified botulinum neurotoxin preparations demonstrate superior antigenicity and immunogenicity compared to commercial options. These optimized toxoids are highly effective for developing diagnostic tools and antitoxins.
Area of Science:
- Immunology
- Microbiology
- Biochemistry
Background:
- Botulinum neurotoxins are potent toxins requiring effective detoxification for safe use in research and antitoxin production.
- Formalin-detoxified toxoids are crucial for developing vaccines and diagnostic assays, but their quality can vary significantly.
- Assessing the antigenicity and immunogenicity of botulinum neurotoxin toxoids is vital for ensuring their efficacy and safety.
Purpose of the Study:
- To synthesize and evaluate novel formalin-detoxified botulinum neurotoxin serotype A preparations.
- To compare the antigenicity and immunogenicity of in-house synthesized toxoids with commercially available toxoids.
- To determine the protective efficacy of the developed toxoids in a mouse model.
Main Methods:
- Formalin-detoxification of botulinum neurotoxin serotype A.
- Antigenicity assessment using inhibition and sandwich enzyme-linked immunosorbent assays (ELISAs).
- Immunogenicity and protective efficacy studies in mice, including antibody titer determination and lethal toxin challenge.
Main Results:
- Three in-house synthesized toxoids were antigenically identical to native neurotoxin, with over 100,000-fold reduction in toxicity.
- In-house toxoids showed significantly higher antigenicity in sandwich ELISAs compared to commercial toxoids.
- Mice immunized with in-house toxoids developed high toxin-specific IgG titers and were protected against lethal botulinum neurotoxin challenge, unlike mice receiving commercial toxoids.
Conclusions:
- Optimized formaldehyde reaction conditions yield highly antigenic and immunogenic botulinum neurotoxin toxoids.
- Inhibition ELISAs effectively predict the immunogenicity and in vivo potency of new toxoids.
- The superior quality of these novel toxoids makes them valuable for ELISA development and antitoxin production.
Related Concept Videos
Botulism
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Tetanus
Bacterial Toxins
Types of Toxins
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Diphtheria

